bcrp - publications

Predict more bcrp - ligand interactions now!

1. Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):916-20.

[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic
response of TE regimen neoadjuvant chemotherapy in breast cancer patients].

[Article in Chinese]

Li X, Li Y, Yang SE, Ma Y, Wen SJ, Guo L, Guli KZ, Zhao B, Liu W, Hu X.

Department of Chemotherapy, Affiliated Tumor Hospital of Medical University,
Urumqi 830011, China.

OBJECTIVE: To study the changes of expression of Survivin mRNA, BCRP mRNA and
HER-2 mRNA in breast cancer after TE regimen neoadjuvant chemotherapy, and to
find biological markers to predict the efficiency of TE regimen neoadjuvant
METHODS: The gene expressions were detected by RT-PCR from 56 breast cancer
patients before and after TE regimen neoadjuvant chemotherapy (docetaxel and
epirubicin). The relationships between these gene expressions and chemotherapy
responses were analyzed.
RESULTS: The overall response rate to neoadjuvant chemotherapy was 71.4%,
including 8.9% (5/56) with complete response and 62.5% (35/56) with partial
response. Pathological complete response was found in 4 cases (7.1%). Stable
disease and progression of disease were 23.2% (13/56) and 5.4% (3/56),
respectively. The expression of Survivin mRN A after neoadjuvant chemotherapy was
35.7% (20/56), significantly lower than 60.7% (34/56) before neoadjuvant
chemotherapy (P = 0.008). The expression of BCRP mRNA after neoadjuvant
chemotherapy was 19.6%, significantly lower than 37.5% before neoadjuvant
chemotherapy (P = 0.036). The positive rate of HER-2 mRNA expression was 41.1%
before the chemotherapy, and reduced to 21.4% after the chemotherapy (P = 0.025).
The effective rates of the single positive expression of Survivin mRNA or BCRP
mRNA were both lower than that of negative expression (P < 0.05). The level of
HER-2 mRNA expression alone was not significantly associated with the effective
rate of chemotherapy (P = 0.144). When the expression of all Survivin mRNA, BCRP
mRNA and HER-2 mRNA were negative, the effective rate of neoadjuvant chemotherapy
was higher than that in patients with positive expression (P = 0.003). The level
of Survivin mRNA expression was not significantly associated with BCRP mRNA and
HER-2 mRNA (P > 0.05).
CONCLUSION: The expression of Survivin in combination with BCRP and HER-2 is
associated with clinical response to TE neoadjuvant chemotherapy in breast
cancer, and can be used as predictive biomarkers for chemosensitivity of TE
regimen neoadjuvant chemotherapy for breast cancer.

PMID: 22340101 [PubMed - in process]